Mattis Dementia Rating Scale
- Introduced by
- Sandra Mattis
- Year
- 1988
- Type
- Clinician-administered comprehensive neuropsychological scale
- Family
- comprehensive dementia assessment
What does it do?
The Mattis Dementia Rating Scale (DRS) is a comprehensive 36-item clinician-administered neuropsychological battery designed to assess and quantify cognitive decline in dementia.
Developed by Sandra Mattis in 1988, the DRS measures five major cognitive domains—attention, initiation/perseveration, construction, conceptualization, and memory—and provides both a total score and subscale scores. The DRS is particularly valued in neurodegenerative disease research and clinical settings for its sensitivity to cognitive change over time and its utility in detecting cognitive impairment across the dementia spectrum.
The intuition behind the method
The DRS was designed to fill a gap between brief cognitive screeners (like the MMSE) and time-intensive comprehensive neuropsychological batteries. It samples the cognitive domains most consistently affected by dementia while remaining efficient enough for clinical use. The inclusion of attention and initiation/perseveration subscales makes the DRS particularly sensitive to subcortical and frontal pathology, distinguishing it from memory-focused instruments. The 144-point total score and detailed subscales allow quantification of cognitive change and differential diagnosis.
History
The Mattis Dementia Rating Scale was developed by Sandra Mattis and published by Psychological Assessment Resources (PAR) in 1988. It emerged from clinical and research experience in neuropsychology, designed to address limitations of existing dementia assessment tools. The DRS became widely adopted in neurodegenerative disease research, particularly in Alzheimer's disease and Parkinson's disease studies. Over the past three decades, extensive normative data have been published for diverse age groups, education levels, and disease populations. The DRS-2 (revised version) was released in 2001 with updated norms and alternative forms.
When to use it
The DRS is indicated for comprehensive cognitive assessment in patients with suspected dementia, particularly when tracking change over time or differentiating between dementia types. It is more thorough than the MMSE and more balanced across cognitive domains than instruments emphasizing memory alone. The DRS is particularly useful in neurodegenerative disease research and in clinical settings where quantification of cognitive impairment is required. It is NOT diagnostic alone and should be integrated with clinical assessment, imaging, and sometimes additional testing.
Limitations and considerations
- Longer than MMSE — 20–30 minutes administration limits utility in very busy primary care settings or patients with limited stamina.
- Language and education dependent — several subscales require verbal responses and intact language ability; results may be confounded in non-native speakers or those with aphasia.
- Requires training — standardized administration and scoring demand clinician expertise; not as straightforward as the MMSE.
- Copyrighted — unlike the MMSE, the DRS is proprietary (Psychological Assessment Resources) and requires licensing.
Source conditions do not replace independent scientific review or validation by an analysis engine.
Strengths
- Comprehensive yet moderately brief — assesses five major cognitive domains in 20–30 minutes, more thorough than MMSE while more efficient than full neuropsychological batteries.
- Sensitive to cognitive change — responsive to disease progression over time; used extensively in Alzheimer's and Parkinson's disease trials.
- Detailed subscales — allow identification of specific cognitive impairment patterns (e.g., predominant memory loss vs. executive dysfunction), informing differential diagnosis.
- Extensive research validation — used in thousands of studies with published normative data across diverse populations and disease groups.
Applications
- Alzheimer's disease drug trial: A pharmaceutical company uses the DRS as a primary cognitive outcome measure in a 12-month, placebo-controlled trial of an anti-amyloid monoclonal antibody. DRS total score and Memory subscale are measured at baseline, 6, and 12 months; the drug-treated group shows slowing of decline compared to placebo on DRS.
- Parkinson's disease cognitive monitoring: A movement disorders neurologist uses serial DRS testing every 6 months to track cognitive decline in a patient with Parkinson's disease dementia. Baseline DRS is 120 (mild-moderate impairment); at 18 months, DRS has declined to 105. The declining Initiation/Perseveration subscale with relative preservation of Memory reflects the subcortical pathology typical of Parkinson's cognitive decline.
- Differential dementia diagnosis: A neuropsychologist evaluates a 72-year-old with cognitive symptoms. DRS total is 110 (moderate impairment). Subscale analysis reveals: Memory 12/25 (markedly impaired), Initiation/Perseveration 20/37 (relatively preserved). This pattern (memory > initiation) suggests cortical (Alzheimer-like) pathology rather than subcortical disease.
- Dementia research cohort: A longitudinal study enrolls 150 patients with mild cognitive impairment and follows them with DRS assessment every 6 months for 3 years. Baseline DRS scores and rate of DRS decline predict conversion to dementia and subsequent functional deterioration.
How it works
How it works
The DRS comprises 36 items administered by a clinician in approximately 20–30 minutes. Five cognitive domains are assessed: Attention (8 items, 0–37 points), Initiation/Perseveration (4 items, 0–37 points), Conceptualization (6 items, 0–39 points), Construction (1 item, 0–6 points), and Memory (17 items, 0–25 points). The examiner presents items in order and scores responses according to the manual criteria.
The DRS total score ranges from 0 to 144, with higher scores indicating better cognitive function. Subscale scores provide details: Attention (0–37), Initiation/Perseveration (0–37), Conceptualization (0–39), Construction (0–6), and Memory (0–25). A DRS total score of <130 is typically associated with cognitive impairment; cutoffs vary by age and education.
A DRS total score of 130–144 indicates normal cognition. Scores of 120–129 suggest mild cognitive impairment. Scores of 80–119 indicate moderate dementia. Scores <80 indicate severe dementia. The subscale pattern is informative: low Initiation/Perseveration combined with relative preservation of Memory suggests subcortical (vascular, Parkinson's) pathology; low Memory with relatively preserved Initiation suggests cortical (Alzheimer's) pathology.
Common pitfalls
- Interpreting DRS total score without examining subscales — the pattern of subscale deficits is diagnostically informative. Always review individual subscale scores.
- Using outdated norms — ensure norms match your population's age, education, and disease status.
- Administering DRS in patients with severe aphasia or motor impairment — several subtests require verbal and motor responses; impairments unrelated to dementia will confound scores.
- Over-interpreting changes over short intervals — practice effects, fatigue, and mood changes can affect DRS scores by 5–10 points over weeks; interpret change cautiously without clinical context.
Frequently asked questions
What does a discrepancy between DRS Memory and Initiation/Perseveration subscales suggest?
If Memory is markedly impaired while Initiation/Perseveration is relatively preserved, the pattern suggests cortical pathology (e.g., Alzheimer's disease). Conversely, if Initiation/Perseveration is impaired with preserved Memory, the pattern suggests subcortical pathology (e.g., Parkinson's disease, vascular dementia). Always consider clinical and imaging findings alongside the DRS pattern.
How does the DRS compare to the MMSE?
The DRS is more comprehensive than the MMSE; it assesses five cognitive domains versus the MMSE's broad screening. The DRS is more sensitive to mild impairment and cognitive change over time. However, the DRS takes longer (20–30 min vs. 5–10 min), is more complex to administer, and is copyrighted (requires licensing). For screening, use MMSE; for detailed assessment or longitudinal monitoring, use DRS.
What is a clinically meaningful change on the DRS?
A DRS change of 5–10 points over 6–12 months typically reflects true cognitive decline in dementia; changes of <5 points may reflect test-retest variability or practice effects. In clinical trials, 3–4 point differences between groups are considered clinically significant. Always interpret DRS change in clinical context; isolated score change without functional decline may not indicate true progression.
Can the DRS be used in non-English speaking patients?
The DRS has been translated into several languages (e.g., Spanish, German, Chinese), but English norms are most extensive. If using a translation, verify that adequate validation and normative data exist for the language and population you're assessing. Consider hiring a bilingual neuropsychologist for valid administration.
Related methods
Sources
Mattis, S. (1988). Dementia Rating Scale (DRS). Odessa, FL: Psychological Assessment Resources.
Open publication referenceCopied.Monsch, A. U., Bondi, M. W., Butters, N., Salmon, D. P., Kluger, A., & Thal, L. J. (1992). Comparisons of verbal and nonverbal cognitive function in Alzheimer's disease. Neurology, 42(8), 1638-1644.
Open publication referenceCopied.Vangel Jr, S. J., & Lichtenberg, P. A. (2008). Mattis Dementia Rating Scale: Clinical utility in older adults. Clinical Neuropsychologist, 22(1), 71-80.
Open publication referenceCopied.